AzTrials
AzTrials

Recurrent Astrocytoma, IDH-Mutant, Grade 4Phase 1NCT07544992

Locoregional Administration of Genetically Engineered Cells (EGFR/IL13Rα2 Pool-CAR T Cells) for the Treatment of Recurrent or Progressive High-Grade Gliomas

A Phase 1 study testing Autologous Anti-EGFR/Anti-IL13Ralpha2 CAR T-cells, Biopsy Procedure and Biospecimen Collection in people with Recurrent Astrocytoma, IDH-Mutant, Grade 4 and Recurrent Glioblastoma, IDH-Wildtype, run by City of Hope Medical Center at 1 site in United States.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record

Search all trials

Trial summary

This phase I trial studies the side effects and best dose of EGFR/IL13Rα2 pool-chimeric antigen receptor (CAR) T cells when given through a thin, flexible tube into the brain (locoregional administration) in treating patients with high-grade gliomas that have come back after a period of improvement (recurrent) or that… Read more about this study

Who is it for?
Ages 18 years and older
What is being tested?
Autologous Anti-EGFR/Anti-IL13Ralpha2 CAR T-cells, Biopsy Procedure and Biospecimen Collection
Type of treatment
Surgery or procedure
Could I receive a placebo?
No, everyone receives an active treatment
How many people
24 participants
Where
1 siteUnited States
Study dates
26 May 2026to 4 Nov 2031
Phase
Phase 1

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Main Inclusion Criteria

  • Documented informed consent of the participant and/or legally authorized representative.
  • Agreement to allow the use of archival tissue from diagnostic tumor biopsies. If unavailable, exceptions may be granted with Study PI approval.
  • Age 18 years and older.
  • KPS ≥ 70%, ECOG ≤ 2 (Appendix A).
  • Life expectancy ≥ 4 weeks.
  • Participant has a prior histologically confirmed diagnosis of a glioblastoma (IDH-wildtype) or grade 4 IDH-mutant astrocytoma, or has a prior histologically confirmed diagnosis of a grade 2 or 3 astrocytoma and now has radiographic progression consistent with grade 4 IDH-mutant astrocytoma.
  • Relapsed disease: radiographic evidence of recurrence/progression of measurable disease after standard therapy (such as temozolomide with or without Optune device), and ≥ 12 weeks after completion of front-line radiation therapy.
  • COH Clinical Pathology assessment at the initial tumor presentation or recurrent disease (reference Appendix B):
  • IL13Rα2+ expression by IHC > 20, and
  • EGFR gene-altered by NGS or FISH analysis
  • No known contraindications to leukapheresis, steroids, imaging studies, or tocilizumab.
  • WBC > 2000 /dl (or ANC ≥ 1,000/mm3)
  • Platelets ≥ 75,000/mm3
  • Hemoglobin > 9g/dL
  • Total bilirubin ≤ 1.5x ULN
  • AST ≤ 2.5x ULN
  • ALT ≤ 2.5x ULN
  • Serum creatinine ≤1.6 mg/dL
  • O2 saturation ≥ 95% on room air.
  • Seronegative for HIV Ag/Ab combo, HCV, and active HBV
  • Women of childbearing potential (WOCBP): negative urine or serum pregnancy test.
  • Agreement by females and males of childbearing potential to use an effective method of birth control or abstain from heterosexual activity for the course of the study through at least 3 months after the last dose of CAR T cells.

Main Exclusion Criteria

  • Owing to higher frequency of wound-related complications, participants who require active bevacizumab therapy at the time of enrollment are excluded.
  • Participant has not yet recovered from toxicities of prior therapy.
  • Participant has received any live vaccine within 30 days prior to enrollment.
  • Uncontrolled seizure activity and/or clinically evident progressive encephalopathy.
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to study agent.
  • Clinically significant uncontrolled illness.
  • Active autoimmune disease requiring systemic immunosuppressive therapy
  • Active infection requiring IV antibiotics (for example, minor scalp infection is not exclusion).
  • Known history of immunodeficiency virus (HIV) or hepatitis B or hepatitis C infection.
  • Other active malignancy.
  • Females only: Pregnant or breastfeeding.
  • Any other condition that would, in the Investigator's judgment, contraindicate the subject's participation in the clinical study due to safety concerns with clinical study procedures.
  • Prospective participants who, in the opinion of the Investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility/logistics).

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

United States1 site, 1 recruiting

  • City of Hope Medical Center

    Duarte, California, 91010

    Behnam Badie, 626-218-7293, braintumortrials@coh.org

    Behnam Badie

    Recruiting

Other trials in United States

About this study

Official title: A Phase 1 Trial to Evaluate the Safety of EGFR/IL13Rα2 Pool-CAR T Cells in Patients With Recurrent or Progressive High-Grade Glioma (HGG)

This phase I trial studies the side effects and best dose of EGFR/IL13Rα2 pool-chimeric antigen receptor (CAR) T cells when given through a thin, flexible tube into the brain (locoregional administration) in treating patients with high-grade gliomas that have come back after a period of improvement (recurrent) or that are growing, spreading, or getting worse (progressive). EGFR/IL13Rα2 pool-CAR T cells are a type of CAR T cell therapy. CAR T cell therapy is a type of treatment in which a patient's T cells (a type of immune system cell) are changed in the laboratory so they will attack tumor cells. T cells are taken from a patient's blood. Then the gene for a special receptor that binds to a certain protein on the patient's tumor cells is added to the T cells in the laboratory. The special receptor is called a CAR. Large numbers of the CAR T cells are grown in the laboratory and given to the patient by infusion for treatment of certain cancers.

Read the detailed description

PRIMARY OBJECTIVE:

  1. Assess the safety and determine the maximum tolerated dose (MTD) of locoregional administration of autologous anti-EGFR/anti-IL13Rα2 CAR T-cells (EGFR/IL13Rα2 pool-CAR T cell) therapy.

SECONDARY OBJECTIVES:

  1. In participants who receive at least 50% of the assigned cell dose for each cycle (1-4) and at least 70% of the total cumulative dose:
  2. Estimate disease control rate (DCR: complete response [CR] + partial response [PR] +stable disease [SD]);
  3. Estimate overall response rate (ORR: CR+PR);
  4. Estimate time to progression (TTP);
  5. Estimate median overall survival, and;
  6. Estimate overall survival (OS) at 12-months.

II. Determine feasibility of locoregionally administered EGFR/IL13Rα2 pool-CAR T cell therapy as assessed by leukapheresis and manufacturing processes, including ability to meet the EGFR/IL13Rα2 pool-CAR T cell dose and product release requirements.

EXPLORATORY OBJECTIVES:

  1. Describe cytokine levels in cerebrospinal fluid (CSF), tumor cavity fluid (TCF), and peripheral blood (PB) over the study period and changes in the presence of cytokines with respect to observed adverse events and treatment outcomes.

II. Describe CAR T cell and endogenous immune cell populations (CSF, TCF, PB).

III. Describe tumor and tumor microenvironment markers and their relationship to treatment outcomes.

IV. Describe potential on-target, off-tumor impact of infused EGFR/IL13Rα2 pool-CAR T cells via the evaluation of testosterone levels.

  1. For participants who undergo secondary resection(s), biopsy(s), or /post-mortem collection:
  2. Evaluate CAR T cell persistence in the tumor microenvironment and location of the CAR T cells with respect to the injection site;
  3. Evaluate changes in IL13Rα2 antigen expression levels and epidermal growth factor receptor (EGFR) gene alterations in pre and post CAR T cell therapy, and;
  4. Evaluate changes in tumor and immune landscape post-therapy.

VI. Descriptively compare IL13Ra2-CAR T cell and EGFR-CAR T cell persistence and expansion dynamics in the CSF and the blood.

VII. Through the use of biomathematical modeling techniques, characterize tumor growth and its relationship to treatment outcomes.

VIII. Evaluate CAR T cell product characteristics.

IX. Assess immune responses directed against EGFR/IL13Rα2 pool-CAR T cells at post-infusion time points.

OUTLINE: This is a dose-escalation study.

Patients undergo leukapheresis followed by surgical resection, biopsy, and intracranial tumoral (ICT) and/or intracranial ventricular (ICV) catheter placement 1-3 weeks prior to cycle 1, day 0. Patients then receive EGFR/IL13Rα2 pool-CAR T cells via ICT and/or ICV catheter over 5 minutes on day 1 of each cycle. Cycles repeat every 7 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients may receive additional cycles of EGFR/IL13Rα2 pool-CAR T cells per principal investigator (PI) and patient discretion and/or undergo additional leukapheresis as needed on study. Patients also undergo echocardiography (ECHO) during screening, as well as fludeoxyglucose (FDG)-positron emission tomography (PET), magnetic resonance imaging (MRI), and blood, TCF, and CSF sample collection throughout the study.

After completion of study treatment, patients are followed up at day 30, months 3, 6, 9, and 12, and then yearly for up to 15 years post last CAR T cell infusion.

Being tested
Autologous Anti-EGFR/Anti-IL13Ralpha2 CAR T-cells, Biopsy Procedure, Biospecimen Collection, Echocardiography Test, FDG-Positron Emission Tomography
Medical subject headings
Astrocytoma, Glioblastoma

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Autologous Anti-EGFR/Anti-IL13Ralpha2 CAR T-cellsBiological

    Also called Autologous Anti-EGFR/Anti-IL13Ra2 CAR T-cells, Autologous Anti-EGFR/IL13Ra2 CAR T Cells, Autologous Anti-EGFR/IL13Ra2 CAR-T Cells, CART-EGFR-IL13Ra2 Cells

    Given via ICT and/or ICV catheter

  • Biopsy ProcedureProcedure or surgery

    Also called Biopsy, BIOPSY_TYPE, Bx

    Undergo biopsy

  • Biospecimen CollectionProcedure or surgery

    Also called Biological Sample Collection, Biospecimen Collected, Specimen Collection

    Undergo blood, TCF, and CSF sample collection

  • Echocardiography TestProcedure or surgery

    Also called EC, Echocardiography

    Undergo ECHO

  • FDG-Positron Emission TomographyProcedure or surgery

    Also called FDG, FDG-PET, FDG-PET Imaging

    Undergo FDG-PET

  • Intracranial Catheter PlacementProcedure or surgery

    Undergo ICT and/or ICV catheter placement

  • LeukapheresisProcedure or surgery

    Also called Leukocyte Adsorptive Apheresis, Leukocytopheresis, Therapeutic Leukopheresis, White Blood Cell Reduction Apheresis

    Undergo leukapheresis

  • Magnetic Resonance ImagingProcedure or surgery

    Also called Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan

    Undergo MRI

  • ResectionProcedure or surgery

    Also called Surgical Resection

    Undergo surgical resection

Study groups in NCT07544992
Study groupRoleWhat they receive
Treatment (EGFR/IL13Rα2 pool-CAR T cell therapy)ExperimentalPatients undergo leukapheresis followed by surgical resection, biopsy, and ICT and/or ICV catheter placement 1-3 weeks prior to cycle 1, day 0. Patients then receive EGFR/IL13Rα2 pool-CAR T cells via ICT and/or ICV catheter over 5 minutes on day 1 of each cycle. Cycles repeat every 7 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients may receive additional cycles of EGFR/IL13Rα2 pool-CAR T cells per PI and patient discretion and/or undergo additional leukapheresis as needed on study. Patients also undergo ECHO during screening, as well as FDG-PET, MRI, and blood, TCF, and CSF sample collection throughout the study.
Receives: Biological: Autologous Anti-EGFR/Anti-IL13Ralpha2 CAR T-cells; Procedure: Biopsy Procedure; Procedure: Biospecimen Collection; Procedure: Echocardiography Test; Procedure: FDG-Positron Emission Tomography; Procedure: Intracranial Catheter Placement; Procedure: Leukapheresis; Procedure: Magnetic Resonance Imaging; Procedure: Resection

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Incidence of adverse events

    Toxicity will be assessed using the Common Terminology Criteria for Adverse Events version 5.0, Cytokine Release Syndrome/Neurotoxicity grading by the American Society for Transplantation and Cellular Therapy Consensus Criteria, Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-Like Syndrome grading system, and Tumor Inflammation-Associated Neurotoxicity grading system.

    Measured: Up to 15 years

  2. Maximum tolerated dose (MTD)

    The MTD will be determined based on dose limiting toxicities (DLTs), toxicities observed in later cycles (5+), and the activity data. Rate and associated 90% Clopper and Pearson binomial confidence limits (90% confidence intervals [CI]) will be estimated for participants experiencing DLTs at the MTD schedule. Tables will be created to summarize all toxicities and side effects by dose, time post treatment, organ, severity, attributions, and arm.

    Measured: Up to 5 years

Secondary outcomes (4)

  1. Disease response

    Assessed using the Response Assessment in Neuro-Oncology Criteria with the need for bevacizumab as an additional indicator of progression. Will be estimated in study participants who received the full schedule of 4 cycles of autologous anti-EGFR/anti-IL13Ralpha2 CAR T-cell (EGFR/IL13Rα2 pool-CAR T cell) therapy.

    Measured: Up to 15 years

  2. Time to progression

    Time to progression is defined as time from surgery/biopsy to last contact or relapse/progression date.

    Measured: From surgery/biopsy to last contact or relapse/progression date, assessed up to 15 years

  3. Overall survival (OS)

    In study participants who received the full schedule of 4 cycles of EGFR/IL13Rα2 pool-CAR T cell therapy, will estimate the rates (90% CI) of OS at 9 months. Kaplan Meier methods will be used to estimate median OS and graph the results.

    Measured: From surgery/biopsy to last contact or death (from any cause), assessed up to 15 years

  4. EGFR/IL13Rα2 pool-CAR T cell product feasibility - leukapheresis and manufacturing processes

    We will determine feasibility of locoregionally administered EGFR/IL13Rα2 pool-CAR T cell therapy as assessed by leukapheresis and manufacturing processes, including ability to meet the EGFR/IL13Rα2 pool-CAR T cell dose and product release requirements.

    Measured: Up to 5 years

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted22 Apr 2026
  2. Study start26 May 2026
  3. Primary completion4 Nov 2031 (estimated)
  4. Study completion4 Nov 2031 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
24 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07544992
Sponsor's protocol ID
25805
Other IDs
NCI-2026-02448, 25805, P30CA033572
Status last verified
Oct 2026
First submitted
16 Apr 2026
Last updated
23 Oct 2026
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in